| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| INCYIncyte Corporation | 20.8B | 105.95 | 706.33 | 14.76% | 24.69% | 25.55% | 1.2% | 0.01 |
| TGTXTG Therapeutics, Inc. | 4.69B | 29.54 | 196.93 | 40.8% | 13.31% | 21.87% | 1.14 | |
| AGIOAgios Pharmaceuticals, Inc. | 1.68B | 28.73 | 2.47 | 36.07% | -8.96% | -31.24% | 0.04 | |
| CLRBCellectar Biosciences, Inc. | 15.9M | 3.75 | -0.09 | -200.99% | 0.03 | |||
| CASICASI Pharmaceuticals, Inc. | 20.96M | 1.02 | -0.40 | -15.77% | -183.93% | -301.8% | 11.96 | |
| VORVor Biopharma Inc. | 323.62M | 14.77 | -0.43 | -94.52% | 0.33 | |||
| FATEFate Therapeutics, Inc. | 124.58M | 1.08 | -0.66 | -78.55% | -21.87% | -66.69% | 0.27 | |
| KPTIKaryopharm Therapeutics Inc. | 131.65M | 7.19 | -0.76 | -0.55% | -87.43% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 59.12M | 69.89M | 43.01M | 94.39M | 117.91M | 0 | 0 | 14.24M | 26.82M | 36.5M |
| Revenue Growth % | -0.1% | 0.18% | -0.38% | 1.19% | 0.25% | -1% | - | - | 0.88% | 0.36% |
| Cost of Goods Sold | 141.83M | 220.16M | 292.68M | 1.4M | 1.32M | 18.77M | 18.78M | 1.7M | 9.5M | 4.17M |
| COGS % of Revenue | 2.4% | 3.15% | 6.8% | 0.01% | 0.01% | - | - | 0.12% | 0.35% | 0.11% |
| Gross Profit | -82.71M | -150.27M | -249.67M | 92.99M | 116.59M | -18.77M | -18.78M | 12.54M | 17.32M | 32.33M |
| Gross Margin % | -1.4% | -2.15% | -5.8% | 0.99% | 0.99% | - | - | 0.88% | 0.65% | 0.89% |
| Gross Profit Growth % | -1.36% | -0.82% | -0.66% | 1.37% | 0.25% | -1.16% | -0% | 1.67% | 0.38% | 0.87% |
| Operating Expenses | 177.82M | 270.88M | 363.81M | 455.47M | 542.93M | 317.14M | 359.64M | 401.58M | 408.81M | 458.07M |
| OpEx % of Revenue | 3.01% | 3.88% | 8.46% | 4.83% | 4.6% | - | - | 28.2% | 15.24% | 12.55% |
| Selling, General & Admin | 35.99M | 50.71M | 71.12M | 114.14M | 132.03M | 106.12M | 121.44M | 121.67M | 119.9M | 156.78M |
| SG&A % of Revenue | 0.61% | 0.73% | 1.65% | 1.21% | 1.12% | - | - | 8.54% | 4.47% | 4.3% |
| Research & Development | 141.83M | 220.16M | 292.68M | 341.32M | 410.89M | 211.02M | 256.97M | 279.91M | 288.9M | 301.29M |
| R&D % of Revenue | 2.4% | 3.15% | 6.8% | 3.62% | 3.48% | - | - | 19.66% | 10.77% | 8.25% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -18.78M | 0 | 0 | 0 |
| Operating Income | -118.7M | -200.99M | -320.79M | -362.48M | -426.33M | -335.92M | -378.42M | -389.05M | -391.49M | -425.74M |
| Operating Margin % | -2.01% | -2.88% | -7.46% | -3.84% | -3.62% | - | - | -27.32% | -14.6% | -11.66% |
| Operating Income Growth % | -1.19% | -0.69% | -0.6% | -0.13% | -0.18% | 0.21% | -0.13% | -0.03% | -0.01% | -0.09% |
| EBITDA | -115.36M | -195.28M | -314.36M | -355.31M | -409.71M | -317.14M | -359.64M | -380.48M | -384.86M | -420.08M |
| EBITDA Margin % | -1.95% | -2.79% | -7.31% | -3.76% | -3.47% | - | - | -26.72% | -14.35% | -11.51% |
| EBITDA Growth % | -1.19% | -0.69% | -0.61% | -0.13% | -0.15% | 0.23% | -0.13% | -0.06% | -0.01% | -0.09% |
| D&A (Non-Cash Add-back) | 3.34M | 5.71M | 6.43M | 7.17M | 16.62M | 18.77M | 18.78M | 8.56M | 6.62M | 5.65M |
| EBIT | -118.7M | -200.99M | -320.79M | -346.03M | -411.47M | -329.31M | -356.51M | -389.05M | -391.49M | -425.74M |
| Net Interest Income | 968K | 2.51M | 6.12M | 16.45M | 14.86M | -11.22M | 836K | 12.79M | 33.34M | 48.08M |
| Interest Income | 968K | 2.51M | 6.12M | 16.45M | 14.86M | 6.61M | 836K | 12.79M | 33.34M | 48.08M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 17.83M | 0 | 0 | 0 | 0 |
| Other Income/Expense | 968K | 2.51M | 6.12M | 16.45M | 14.86M | 6.61M | 21.91M | 157.25M | 39.4M | 1.14B |
| Pretax Income | -117.73M | -198.47M | -314.67M | -346.03M | -411.47M | -329.31M | -356.51M | -231.8M | -352.09M | 717.97M |
| Pretax Margin % | -1.99% | -2.84% | -7.32% | -3.67% | -3.49% | - | - | -16.28% | -13.13% | 19.67% |
| Income Tax | -426K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44.24M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 0.99% | -4.5% | 1% | 1% | 0.94% |
| Net Income | -117.73M | -198.47M | -314.67M | -346.03M | -411.47M | -327.37M | 1.6B | -231.8M | -352.09M | 673.73M |
| Net Margin % | -1.99% | -2.84% | -7.32% | -3.67% | -3.49% | - | - | -16.28% | -13.13% | 18.46% |
| Net Income Growth % | -1.2% | -0.69% | -0.59% | -0.1% | -0.19% | 0.2% | 5.9% | -1.14% | -0.52% | 2.91% |
| Net Income (Continuing) | -117.73M | -198.47M | -314.67M | -346.03M | -411.47M | -329.31M | -356.51M | -231.8M | -352.09M | 673.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 1.94M | 1.96B | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.15 | -5.07 | -6.75 | -6.03 | -6.61 | -4.74 | -6.36 | -4.23 | -6.33 | 11.64 |
| EPS Growth % | -0.98% | -0.61% | -0.33% | 0.11% | -0.1% | 0.28% | -0.34% | 0.33% | -0.5% | 2.84% |
| EPS (Basic) | -3.15 | -5.07 | -6.75 | -6.03 | -6.61 | -4.74 | -6.36 | -4.23 | -6.33 | 11.86 |
| Diluted Shares Outstanding | 37.43M | 39.13M | 46.59M | 57.42M | 59.99M | 69M | 60.45M | 54.79M | 55.65M | 57.89M |
| Basic Shares Outstanding | 37.43M | 39.13M | 46.59M | 57.42M | 59.99M | 69M | 60.45M | 54.79M | 55.65M | 56.81M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 337.33M | 559.89M | 445.26M | 613.78M | 611.7M | 636.68M | 1.06B | 832.77M | 833.84M | 965.6M |
| Cash & Short-Term Investments | 375.91M | 573.56M | 567.75M | 805.42M | 564.88M | 572.93M | 1.02B | 783.12M | 776.93M | 893.71M |
| Cash Only | 375.91M | 573.56M | 567.75M | 805.42M | 80.93M | 127.44M | 203.13M | 139.26M | 88.2M | 76.25M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 483.95M | 445.49M | 816.89M | 643.86M | 688.72M | 817.46M |
| Accounts Receivable | 11.6M | 8.31M | 3.67M | 10.44M | 15.32M | 0 | 4.38M | 2.21M | 2.81M | 4.11M |
| Days Sales Outstanding | 71.61 | 43.42 | 31.14 | 40.38 | 47.42 | - | - | 56.54 | 38.24 | 41.09 |
| Inventory | -58.91M | -32.25M | -143.81M | 869K | 7.33M | 0 | 0 | 8.49M | 19.08M | 27.62M |
| Days Inventory Outstanding | - | - | - | 227.05 | 2.03K | - | - | 1.82K | 732.61 | 2.42K |
| Other Current Assets | 0 | 0 | 0 | 17.17M | 0 | 63.75M | 0 | 38.95M | 35.02M | 40.16M |
| Total Non-Current Assets | 82.74M | 59.2M | 169.14M | 244.68M | 279.04M | 216.27M | 373.5M | 405.95M | 103.28M | 697.6M |
| Property, Plant & Equipment | 23.22M | 25.34M | 24.43M | 24.32M | 126.11M | 116.07M | 104.23M | 88.12M | 69.79M | 54.55M |
| Fixed Asset Turnover | 2.55x | 2.76x | 1.76x | 3.88x | 0.94x | - | - | 0.16x | 0.38x | 0.67x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 58.91M | 32.25M | 143.81M | 220.12M | 152.93M | 97.61M | 266.38M | 313.87M | 29.43M | 638.32M |
| Other Non-Current Assets | 611K | 1.61M | 891K | 238K | 0 | 2.6M | 2.9M | 3.96M | 4.06M | 4.72M |
| Total Assets | 420.06M | 619.09M | 614.4M | 858.46M | 890.74M | 852.95M | 1.44B | 1.24B | 937.12M | 1.66B |
| Asset Turnover | 0.14x | 0.11x | 0.07x | 0.11x | 0.13x | - | - | 0.01x | 0.03x | 0.02x |
| Asset Growth % | -0.15% | 0.47% | -0.01% | 0.4% | 0.04% | -0.04% | 0.69% | -0.14% | -0.24% | 0.77% |
| Total Current Liabilities | 52.89M | 88.43M | 94.94M | 93.5M | 92.89M | 94.39M | 59.83M | 62.63M | 67.95M | 81.16M |
| Accounts Payable | 14.75M | 17.11M | 22.77M | 17.88M | 21.9M | 17.72M | 16.7M | 18.62M | 9.78M | 16.64M |
| Days Payables Outstanding | 37.95 | 28.36 | 28.39 | 4.67K | 6.07K | 344.62 | 324.63 | 3.99K | 375.6 | 1.46K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 7.41M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.47M | 24.32M | 18.64M | 22.07M | 18.98M | 48.91M | 19.82M | 12.24M | 23.23M | 46.86M |
| Current Ratio | 6.38x | 6.33x | 4.69x | 6.56x | 6.59x | 6.74x | 17.79x | 13.30x | 12.27x | 11.90x |
| Quick Ratio | 7.49x | 6.70x | 6.20x | 6.55x | 6.51x | 6.74x | 17.79x | 13.16x | 11.99x | 11.56x |
| Cash Conversion Cycle | - | - | - | -4.4K | -3.99K | - | - | -2.11K | 395.25 | 1K |
| Total Non-Current Liabilities | 22.06M | 172.07M | 143.95M | 77.42M | 157.33M | 359.06M | 85.94M | 75.28M | 58.14M | 41.09M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 106.75M | 97.79M | 85.94M | 72M | 56.99M | 40.21M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 17.36M | 17.77M | 18.16M | 17.61M | 0 | 261.27M | 0 | 3.28M | 1.16M | 880K |
| Total Liabilities | 74.95M | 260.5M | 238.89M | 170.92M | 250.21M | 453.45M | 145.76M | 137.9M | 126.1M | 122.24M |
| Total Debt | 0 | 0 | 0 | 0 | 113.66M | 105.2M | 97.09M | 85.66M | 72M | 56.99M |
| Net Debt | -375.91M | -573.56M | -567.75M | -805.42M | 32.73M | -22.24M | -106.03M | -53.6M | -16.21M | -19.26M |
| Debt / Equity | - | - | - | - | 0.18x | 0.26x | 0.08x | 0.08x | 0.09x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | -18.84x | - | - | - | - |
| Total Equity | 345.12M | 358.59M | 375.5M | 687.54M | 640.53M | 399.5M | 1.29B | 1.1B | 811.02M | 1.54B |
| Equity Growth % | -0.19% | 0.04% | 0.05% | 0.83% | -0.07% | -0.38% | 2.23% | -0.15% | -0.26% | 0.9% |
| Book Value per Share | 9.22 | 9.16 | 8.06 | 11.97 | 10.68 | 5.79 | 21.37 | 20.09 | 14.57 | 26.62 |
| Total Shareholders' Equity | 345.12M | 358.59M | 375.5M | 687.54M | 640.53M | 399.5M | 1.29B | 1.1B | 811.02M | 1.54B |
| Common Stock | 38K | 42K | 49K | 58K | 68K | 69K | 71K | 71K | 72K | 73K |
| Retained Earnings | -284.68M | -483.15M | -798.06M | -1.1B | -1.52B | -1.84B | -238.76M | -470.56M | -822.65M | -148.92M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -802.49M | -802.49M | -802.49M | -802.49M |
| Accumulated OCI | -318K | -313K | -1.39M | -2.17M | 202K | 105K | -1.2M | -12.54M | -441K | -1.52M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -76.95M | 38.56M | -285.23M | -304.42M | -370.62M | -290.76M | -407.32M | -309.48M | -296.06M | -389.84M |
| Operating CF Margin % | -1.3% | 0.55% | -6.63% | -3.23% | -3.14% | - | - | -21.73% | -11.04% | -10.68% |
| Operating CF Growth % | -0.3% | 1.5% | -8.4% | -0.07% | -0.22% | 0.22% | -0.4% | 0.24% | 0.04% | -0.32% |
| Net Income | -117.73M | -198.47M | -314.67M | -346.03M | -411.47M | -329.31M | -356.51M | -231.8M | -352.09M | 673.73M |
| Depreciation & Amortization | 3.34M | 5.71M | 6.43M | 7.17M | 8.09M | 18.77M | 9.24M | 8.56M | 6.62M | 5.65M |
| Stock-Based Compensation | 31.96M | 42.09M | 47.81M | 73.36M | 72.37M | 0 | 53.51M | 49.3M | 44.77M | 42.85M |
| Deferred Taxes | 0 | 0 | 0 | 0 | -2.14M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 572K | 773K | 29K | -3.82M | 8.53M | 17.81M | -76.74M | -119.1M | 23.69M | -1.09B |
| Working Capital Changes | 4.91M | 188.47M | -24.83M | -35.1M | -46M | 1.97M | -36.82M | -16.43M | -19.06M | -19.77M |
| Change in Receivables | -1.73M | 3.34M | 1.22M | -6.1M | -3.62M | 0 | -4.38M | -2.21M | -604K | -1.3M |
| Change in Inventory | -3.17M | 14.43M | -2.08M | -869K | -6.46M | -7.37M | 0 | -8.49M | -10.58M | -8.54M |
| Change in Payables | 4.21M | 3.5M | 5.33M | -5.49M | 3.72M | 3.33M | 1.86M | 3.44M | -8.73M | 6.6M |
| Cash from Investing | 128.31M | -119.35M | -57.91M | -273.82M | 91.44M | 75.75M | 1.25B | 243.26M | 239.57M | 363.44M |
| Capital Expenditures | -20.16M | -9.91M | -4.63M | -6.99M | -12.17M | -14.11M | -5.74M | -4.88M | -999K | -1.69M |
| CapEx % of Revenue | 0.34% | 0.14% | 0.11% | 0.07% | 0.1% | - | - | 0.34% | 0.04% | 0.05% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 148.47M | -109.44M | -53.28M | -266.84M | 103.47M | -803K | 1.8B | 0 | -16.18M | 1.09B |
| Cash from Financing | 6.37M | 169.78M | 285.11M | 546.02M | 289.61M | 261.52M | -765.77M | 2.35M | 5.43M | 14.44M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 6.37M | 7.63M | 14.86M | 29.82M | 12.52M | 250.54M | 37.3M | 0 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -97.11M | 28.65M | -289.86M | -311.41M | -382.79M | -304.87M | -413.06M | -314.36M | -297.06M | -391.53M |
| FCF Margin % | -1.64% | 0.41% | -6.74% | -3.3% | -3.25% | - | - | -22.08% | -11.07% | -10.73% |
| FCF Growth % | -0.58% | 1.29% | -11.12% | -0.07% | -0.23% | 0.2% | -0.35% | 0.24% | 0.06% | -0.32% |
| FCF per Share | -2.59 | 0.73 | -6.22 | -5.42 | -6.38 | -4.42 | -6.83 | -5.74 | -5.34 | -6.76 |
| FCF Conversion (FCF/Net Income) | 0.65x | -0.19x | 0.91x | 0.88x | 0.90x | 0.89x | -0.25x | 1.34x | 0.84x | -0.58x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 16.08M | 0 | 1.57M | 43.15M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -30.6% | -56.41% | -85.73% | -65.1% | -61.97% | -62.95% | 189.74% | -19.38% | -36.83% | 57.29% |
| Return on Invested Capital (ROIC) | -46.91% | - | - | - | -115.15% | -47.96% | -36.31% | -26.13% | -31.88% | -27.57% |
| Gross Margin | -139.9% | -215% | -580.48% | 98.52% | 98.88% | - | - | 88.03% | 64.57% | 88.59% |
| Net Margin | -199.14% | -283.97% | -731.6% | -366.61% | -348.97% | - | - | -1627.82% | -1312.63% | 1845.92% |
| Debt / Equity | - | - | - | - | 0.18x | 0.26x | 0.08x | 0.08x | 0.09x | 0.04x |
| Interest Coverage | - | - | - | - | - | -18.84x | - | - | - | - |
| FCF Conversion | 0.65x | -0.19x | 0.91x | 0.88x | 0.90x | 0.89x | -0.25x | 1.34x | 0.84x | -0.58x |
| Revenue Growth | -9.55% | 18.22% | -38.46% | 119.45% | 24.92% | -100% | - | - | 88.36% | 36.07% |
| 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Product | 13.84M | 59.85M | 121.09M | 11.74M | 26.82M | 36.5M |
| Product Growth | - | 332.42% | 102.32% | -90.30% | 128.48% | 36.07% |
| Royalty | 7.21M | 10.54M | 10.26M | 2.5M | - | - |
| Royalty Growth | - | 46.11% | -2.66% | -75.64% | - | - |
| Collaboration Revenue, Related Party | 60.66M | 39.26M | 68.27M | - | - | - |
| Collaboration Revenue, Related Party Growth | - | -35.28% | 73.92% | - | - | - |
| Research Services | - | 35.95M | 64.35M | - | - | - |
| Research Services Growth | - | - | 78.97% | - | - | - |
| Commercialization Activity | - | 3.3M | 3.93M | - | - | - |
| Commercialization Activity Growth | - | - | 18.89% | - | - | - |
| Development Activities | - | - | - | - | - | - |
| Development Activities Growth | - | - | - | - | - | - |
| Committee Participation | - | - | - | - | - | - |
| Committee Participation Growth | - | - | - | - | - | - |
| Collaboration Revenue, Other | 12.67M | 8.26M | - | - | - | - |
| Collaboration Revenue, Other Growth | - | -34.79% | - | - | - | - |
Agios Pharmaceuticals, Inc. (AGIO) has a price-to-earnings (P/E) ratio of 2.5x. This may indicate the stock is undervalued or faces growth challenges.
Agios Pharmaceuticals, Inc. (AGIO) reported $44.8M in revenue for fiscal year 2024. This represents a 105% increase from $21.8M in 2011.
Agios Pharmaceuticals, Inc. (AGIO) grew revenue by 36.1% over the past year. This is strong growth.
Agios Pharmaceuticals, Inc. (AGIO) reported a net loss of $401.3M for fiscal year 2024.
Agios Pharmaceuticals, Inc. (AGIO) has a return on equity (ROE) of 57.3%. This is excellent, indicating efficient use of shareholder capital.
Agios Pharmaceuticals, Inc. (AGIO) had negative free cash flow of $414.1M in fiscal year 2024, likely due to heavy capital investments.